T
I
G
E
R
M
E
D
01
ConTenTs
Tigermed
Sustainability report
LEADING CHANGE
While the world is facing unprecedented changes in decades, changing to respond
to change and welcoming change over responding. Tigermed proactively adapts to
changes in regulations, customer needs and social patterns, and keeps innovating its own
mindsets, technologies and operational models to lead industry development.
Amidst complex changes, keeping a clear goal helps one stay on course. Tigermed stays
true to the mission of "serving healthcare partners through innovation, advancing human
health through excellence", and builds itself on the core values – honest & reliable, open &
inclusive, collaborative & accountable, professional & innovative. Tigermed positions itself
as a compliant business and works hand in hand with stakeholders towards sustainability.
CoNtENts Driving innovation guiDing our PeoPle in the
of CliniCal researCh 20 Quest for suCCess 38
02 LEADER'S SPEECH 52 KEY PERFORMANCE
PoWeRInG GLoBAL MeDICAL InnoVATIon 22 ensURInG eMPLoYees' BAsIC RIGHTs AnD InTeResTs 40
04 ABOUT TIGERMED BeCoMInG A TRUsTeD CLInICAL ReseARCH PARTneR 25 ACTIVAInG TALenT AnD UnLeAsHInG PoTenTIAL 42 54 OUTLOOK
UPHoLDInG QUALITY As THe CoRe oF THe BUsIness FosTeRInG An enGAGInG TIGeRMeD CULTURe
08 CORPORATE GOVERNANCE 56 HONG KONG STOCK EXCHANGE
28 44
ESG (ENVIRONMENTAL, SOCIAL AND
16 FEATURE: COUNTERMARCHING,
Promoting inDustry Contributing to a GOVERNANCE) REPORTING GUIDE INDEX
IN THE FIGHT AGAINST COVID-19
DeveloPment 30 shareD future 46
58 GRI (GLOBAL REPORTING INITIATIVE)
ACCeLeRATInG THe DeVeLoPMenT oF HeALTH InDUsTRY LoCALLY 32 GReen TIGeRMeD: sTRenGTHenInG 48 INDEX
enVIRonMenTAL MAnAGeMenT
sHARInG IDeAs AnD ResoURCes WITH InDUsTRY PeeRs 34
CARInG TIGeRMeD: IMPRoVInG HeALTH
60 ABOUT THIS REPORT
BUILDInG A sTRonG TALenT PooL FoR HIGH-QUALITY InDUsTRY
50
36
AWAReness AT CoMMUnITY LeVeL
DeVeLoPMenT
02 01
LeADeR's sPeeCH
Tigermed
Sustainability report
In the past 2019, Tigermed worked towards accelerating the 100% of top ten customers. such a success hinged upon the fast in work practice and are entrusted with key positions. Many
launch of more innovative drugs for the benefit of patients. We pragmatic cooperation of our clinical research team. Through senior managers are veteran employees who have worked
yielded fruitful results and ushered in a number of important industrial chain extension and regional service capacity with us for over ten years. We believe the development of the
milestones. building, we provided customers with all-round solutions, Company and the growth of employees go hand in hand.
timely response and effective countermeasures to address their
During the year, the continued reform of China's drug and demands. We have witnessed the development of innovative drugs in
medical device reviewing and approval brought us new China over the past 10 years. Drug innovation in China evolved
opportunities and challenges. We concentrated our efforts on This year, we continued to expand our business landscape from one man's fight to a battle of thousands of innovators,
innovative drugs and medical devices, and put more health in the Asia Pacific Region, europe and the United states, and in the meantime, the regulatory system keeps innovating
to LEAD products to the market to drive the development of innovative
drugs in China. We were behind a number of innovative
products, such as BeiGene's Zanubrutinib, the first FDA-
and further internationalized ourselves. We set up a joint
venture with the Japanese company Accerise Inc. to provide
international multi-center clinical trial services in Japan.
in alignment with global practices. We have deeply felt the
profound changes of the era, thus upgrading ourselves
proactively to adapt to changes in regulations, customer needs,
to INNovAtE approved anti-cancer drug developed in China, the first China-
made biosimilar Rituximab Injection developed by Henlius, and
the first China-made artificial heart "Yongrenxin". As of the first
our first international multi-center clinical trial in singapore
enrolled the first subject. We acquired 100% stake in
Tigermed-BDM Inc. in U.s. and integrated its data statistics
and social and cultural patterns. We keep innovating our own
mindsets, technologies, service and operational models to
respond to changes in the pharmaceutical industry and the
quarter of 2020, we had helped cumulatively 36 Chinese Class and management resources into ours to adapt to global rapid growth of the Company. our robust growth is predicated
I innovative drugs go on the market, rendering patients more competition. By the end of the reporting period, we have set up on the commitment to corporate mission and values, and on
" We have deeply felt the profound changes of
the era, thus upgrading ourselves proactively
options.
In 2019, our projects passed numerous inspections with
outstanding performance, and won wide recognition from
17 overseas operation sites across 12 countries and regions in
the Asia-Pacific region, north America and europe to fuel drug
clinical trials by leveraging the wide-coverage service network.
compliance management, which underpin our ability to lead
the change.
Looking forward to 2020, Tigermed will ride the trend of
to adapt to changes in regulations, customer
customers. We took pride in the trophies and letters of thanks 2019 was a year of milestones. We released the first social worldwide innovation and waves of continued reform in the
needs, and social and cultural patterns. handed to us: Hua Medicine (shanghai) granted us the Handin- responsibility report to demonstrate our responsibilities, Chinese pharmaceutical industry, and continue to fulfill its
Hand Progress Award; Hutchison MediPharma (shanghai) commitments and practices. our subsidiary, Frontage Holdings mission. We will adhere to the strategy of "Global excellence,
We keep innovating our own mindsets,
bestowed Hangzhou simo the excellent Team Award; and (1521 HK), launched a listing on the Hong Kong stock exchange China expertise", and align with high quality standards in the
technologies, service and operational models 3DMed named Fantastic Bioimaging the Best Partner. We are to further globalize itself as a pharmaceutical CRo. Hangzhou R&D of CoVID-19 drugs. We will fuel the clinical development of
chosen by more customers , and every year we remained Combak Hospital Co., Ltd. passed the GCP accreditation and more new drugs through efficient operation, and contribute to
to respond to changes in the pharmaceutical
obtained the Qualification Certificate of Drug Clinical Trial the health of humankind.
i n d u st r y a n d t h e ra p i d g ro w t h o f t h e Institution. "small shield" APP developed by Hangzhou
slanHealth Co., Ltd., our investee, was successfully licensed
Company.
" as a medical device – an Auxiliary Management software for
Prevention Mother-to-Child Transmission of Viral Hepatitis B
（VHB） by Zhejiang Medical Products Administration.
Product quality is the lifeline of Tigermed, and the foundation
of all our accomplishments. not long after our inception, we
developed a quality management system in line with ICH-GCP
Guideline to ensure project quality. We have fostered a quality
culture to raise employees' quality awareness and gradually
influence their work pattern and mindset. In the meantime, we
incorporate the same quality standards into the supply chain
to tighten quality management with suppliers. our priority on
quality wins us lasting trust from and cooperation with more
customers.
Dedication of every employee has led to Tigermed's sustained
and rapid growth. As talent is the most important asset of
a CRo, we have developed management systems for talent
selection, employment, training and retention, and customized
management and training systems for professional and
managerial personnel respectively. We are proud that our mid-
Dr. Ye Xiaoping level and above managers benefit a lot from internal training. Ms. Cao Xiaochun
Co-founder and Chairman Many employees have joined us right after graduation, grown Co-founder and General Manager
02 03
ABoUT TIGeRMeD
Tigermed
Sustainability report
Regulatory Affairs
Clinical Operations
Biometrics
solutions
Integrated Technology Services
Medical Devices / IVD
Post-Marketing / Real World
Evidence / Vaccine
About
tIGErmED business overview
Tigermed builds an integrated and all-round platform that covers the whole industrial chain
of clinical research, and spans across the overall development cycle of new drugs and medical
Hangzhou Tigermed Consulting Co., Ltd. is committed to supporting clients in their clinical devices. In the pre-clinical stage, we offer bioanalysis, pharmaceutical research (including
The Company was listed on
development in the best possible way. As the leading clinical Contract Research organization Chemistry, Manufacturing and Control), bio-equivalency (Be) trials, and PK/PD services. For Phase
the Growth enterprise Market
(CRo) in China, Tigermed is dedicated to provide services for new drug research and development (GeM) of the shenzhen stock I to IV trials, our service covers project management and implementation, medical writing (such
and other supporting services to global and Chinese pharmaceutical and biotechnology exchange (stock code: 300347.
as clinical protocol and report), clinical monitoring, data management and statistical analysis,
sZ) on August 17, 2012, and on
companies. since our inception in 2004, Tigermed has always embraced new technologies and central imaging, pharmacovigilance, and site management organization (sMo). In addition, we
the main board of the Hong
partnerships to accelerate product development and generate the clinical evidence that our Kong stock exchange on August provide regulatory submission & approval service, medical translation, Good Manufacturing
clients require to demonstrate real-world value. 7, 2020 (stock code: 3347.HK).
Practice (GMP) qualification, training and auditing, and other integrated clinical services for
medical devices from pre-clinical to post-launch stage.
04 05
ABoUT TIGeRMeD
Tigermed
Sustainability report
honors
Mission
Serve healthcare partners
through innovation, Advance
human health through excellence
Vision tigermed
To be the recognized as the leading CRO
Values The 11th China Healthcare summit of entrepreneurs, scientists,
Honest & Reliable, Open & Inclusive, Collaborative & Accountable, Professional & Innovative The 12th China Pharmaceutical strategy Conference co- and Investors and Pharmaceutical Achievement exhibition of
sponsored by China national Pharmaceutical Industry the 70th Anniversary of the Founding of the P.R.C. held by China
Information Center and Taizhou Medical new & High-tech Pharmaceutical enterprises Association and China Medicinal
Brand slogan Industrial Development Zone's Management Committee Biotech Association
Global Excellence, China Expertise
Trusted Clinical Research Organization partner
innovative Chinese Cro of 2019 "top 10 Chinese listed Pharmaceutical
Patient operational Quality Continuous Companies in investment value of 2019";
Centric excellence Priority innovation and "outstanding enterprises of the
Pharmaceutical industry in Celebration of
By collaborating We are committed to We strictly abide by the Looking forward "2020 China enterprise Credit Development Forum and
closely with regulatory building a stable and ethics and regulations to the future, we the 11th Integrity Public Welfare Ceremony" held by China
agencies, medical high-quality team in clinical research challenge ourselves enterprise Reform and Development society Association the 70th anniversary of the founding of the
research institutes, with a strong sense and are committed to explore innovative and China Cooperative Trade enterprises Association
hospitals, and our of responsibility. We to quality. To this solutions internally and P.r.C."
global customers, we provide professional purpose, we provide externally. Through
provide high-quality services and execute standardized, efficient, continuous optimization 2019 top 500 trustworthy listed
medical solutions for efficiently through rapid and proven clinical trial
unmet patient needs. response and internal services and we assure
and breakthroughs,
we enable our clients
Companies in China
coordination. product safety with a to market their
scientific, rigorous, and products successfully
professional attitude. worldwide and to Hangzhou Municipal Zhejiang Association for Corporate social
ensure the sustainable Hua Medicine (shanghai) Ltd. Bureau of Commerce Responsibility
development of our
company.
1898 hand-in-hand Progress model hangzhou 2019 model Company in
number of total customers
(by the end of the reporting award Company in Corporate social responsibility
Headquartered in Hangzhou, Tigermed runs 123 service outlets in China's mainland, Hong Kong period)
and Taiwan.To drive the internationalization of pharmaceutical R&D, the Company has also
service and trade in zhejiang Province
opened overseas subsidiaries and offices in 10 countries and regions, including Korea, Japan, (for Practice Dimension)
Malaysia, the United states, Romania and switzerland. 130+
number of global hangzhou simo fantastic bioimaging
branches and service
outlets (as of Q1 2020)
The District economic Work Conference and Mobilization
switzerlanD CanaDa Hutchison MediPharma (shanghai) Ltd. Meeting for Building the strongest Digital economy Zone
romania held by Hangzhou High-Tech Zone (Binjiang)
JaPan usa 36 excellent team award
Korea number of Class I Chinese
excellent young eagle enterprise
innovative drugs successfully
inDia launched (as of Q1 2020)
Beijing Cancer Hospital
malaysia
singaPore 3DMed
According to the report of 2019 beijing Cancer hospital best smo
Frost & sullivan, Tigermed has
become the largest clinical award for Clinical trials best Partner award
CRo in China and among top
ten in the world in terms of the
australia operating revenue of 2019.
frontage laboratories Life science Leader magazine 2019 Cro leadership awards
06 07
CoRPoRATe GoVeRnAnCe
Tigermed
Sustainability report
CorporAtE general meeting of
We hold general meetings of shareholders as required, and facilitate shareholders'
participation so that they can fully exercise their rights. Certain proceedings are
followed for the deliberation of each proposal to ensure all shareholders are
GovErNANCE shareholders treated equally. shareholders' inquiries will be answered, and their suggestions and
opinions be listened to. The discourse right of small and medium shareholders will
be ensured.
overview
We comprehensively consider age, education
Composition of the Fourth
In accordance with the law, we have established the general meeting of shareholders, the Board ba c kg ro u n d , p ro fe s s i o n a l ex p e r i e n ce , s k i l l s ,
of Directors and the Board of supervisors, launched a system of independent directors, and set 6 board of
and industry experience of directors to ensure
Board of Directors by Age:
up special committees under the Board. We have clearly defined the roles, powers, procedures number of general meetings of diversification of the Board. In April 2020, the
and obligations of the general meeting, the Board of Directors, the Board of supervisors and the shareholders Directors Company held a re-election for the fourth Board 1 5
management in decision-making, implementation and supervision. As a result, we have leveraged Membership which comprises three non-independent Aged 40-49 Aged 50-59
directors and three independent directors. Among
well according to the duties of authorities, decision-makers, business units, and supervisors,
creating a governance mechanism of checks and balances. We act in strict accordance with the
15 them, 50% i.e.,three are female.
Company Law of the People's Republic of China , the securities Law of the People's Republic of number of meetings of the Board
of Directors
China and regulations, as well as the internal control system including the Articles of Association ,
the Rules of Procedure of General Meeting , and the Procedural Rules of the Board of Directors to The Fourth Board of supervisors comprises two
continuously improve the corporate governance system, and lay a solid foundation for regulated
operations and sustainable development.
8 shareholder super visors and one employee
supervisor, two of which are male and one is female.
Composition of the Fourth
Board of supervisors by Age:
number of meetings of the Board
of supervisors board of The shareholder and employee supervisors are
During the reporting period, as our international development strategy was further implemented,
supervisors respectively elected by the general meeting of
1 2
and the industrial chain continued to extend, we launched organizational reforms and built shareholders and the staff Representative Meeting.
a "headquarters + business units" structure to empower the headquarters in creating value. The term of office of supervisors is 3 years. Aged 30-39 Aged 50-59
We have established six business units and functional headquarters to better accommodate
development needs.
President Office of Administration
In accordance with the requirements of the relevant laws, regulations and the
Finance Department Management system for Investor Relations , the Company designated the secretary
Audit Committee to the Board as the person-in-charge for the management of investor relations, who
Human Resources Department
is responsible for coordinating investor relations, receiving visiting shareholders,
Remuneration and
Evaluation Committee Quality Assurance Department Internal Audit
investor relationship answering enquires from investors and providing them with information already
Department management disclosed by the Company. The Company responds to enquires from investors
Strategic Development Data Resources and Compliance Department
by means of phone calls, e-mails, interactive investor relations platform, investor
Committee Legal Affairs
Marketing and Business Development Department Department relations section in the corporate website, investor reception day, etc, which
Nomination Committee enhances the exchange of information and promotes positive interactions with
executive vice President Policy and Regulatory Affairs Department investors.
Government Affairs Department
board of Directors President / Ceo
Administration Department The Company discloses its information in a true, accurate, complete and timely
Chief operating officer
Board Secretary
Procurement Department
manner in strict compliance with the relevant laws and regulations and the
information Management system for Information Disclosure . During the reporting period, the
Tigermed Investment Chief financial officer IT Department
Disclosure Company issued a total of 4 periodic reports and 212 temporary announcements
via the media outlets designated by the CsRC,namely The securities Times and the
Innovation Center
Preclinical and Generic Drug CnInFo website (www.cninfo.com.cn).
Business Department Chief science officer
Innovative Drugs Business Department
Medical Devices Business Department
In 2019
Biometrics Business Department 2.78 269.9168
Dividend per 10 shares Total cash dividend
SMO Business Department (tax included) （RMB） (including share repurchase in 2019) （million RMB）
New Industry Development Department
08 09
CoRPoRATe GoVeRnAnCe
Tigermed
Sustainability report
Raising Employees' Anti- Launching Internal Audits
corruption Awareness
W e h a ve e sta b l i s h e d a n i n te r n a l s u p e r v i s i o n a n d
Anti-corruption has been incorporated into our routine management system composed of both business units
training. We cover all employees with anti-corruption and functional departments, such as risk supervision,
training and assessment to raise their compliance compliance management, and audit departments. A multi-
awareness. During the reporting period, we provided level supervision mechanism was also put in place to cover
special anti-corruption training to the management, the headquarters, subsidiaries & branches and business
including members of the Board, to enhance compliance units, to supervise and inspect the Company's financial
awareness at the leadership level in clinical research and status, operation & management, salary distribution, and
business operation. the performance of directors and senior executives on
either a regular or irregular basis. The audit department
should inspect and evaluate the audit supervision of the
headquarters and holding and joint-stock companies, and
submit internal audit reports to the Board of Directors.
Protecting the Rights and
Interests of Whistleblowers
Protection of privacy: The personal information and Strengthening Supply Chain
tips provided by the whistleblowers are kept strictly Compliance Management
confidential. other units, departments and individuals have
no right to access the information unless authorized.
We integrate compliance requirements for suppliers
Guard against retaliation: We have set up a mechanism into our anti-briber y and anti-corruption policies.
to guard against retaliation against informants. When the C o o p e ra t i o n i s g r o u n d e d o n o b s e r v a n c e o f t h e
Compliance management
reports come from the inside, the Company will follow up aforementioned requirements. Suppliers should sign a
to protect whistleblowers from workplace exclusion and third-party anti-bribery and anti-corruption statement
retaliation. When the reports come from suppliers and in the bidding process, which specifies that suppliers
partners, the Company will take measures to protect their shall not offer economic incentives in any form to
Tigermed's steady development cannot be separated from its culture of compliance, integrity 100% rights and interests. once it is confirmed that the informant Tigermed employees. With these measures, we swear to
and honesty. We strictly abide by national laws and regulations, international conventions and Coverage of staff anti-corruption has been retaliated, the Company will strictly deal with the strengthen compliance management from the very start
business ethics, and constantly improve the internal supervision mechanism and risk control training personnel involved. of the supply chain.
system. We boost integrity management to adapt to increasingly stringent supervision and
regulations, and live up to compliance requirements for internationalization. in 2019
The column of "Compliance Concern" was opened up on the home page of our official website.
According to the General Data
Anti-corruption Protection Regulation (GDPR)
Official website Informants shall fill in the form according to the guidance and may choose to report either
anonymously or in real name.
of the european Union, we have
We conduct business with high ethical standards and strictly implement Policies of Anti-bribery improved soPs and management
systems regarding legal affairs, Hotline Tip-off hotline for noncompliant conducts: 400-687-272-02
and Anti-corruption of Tigermed and Policies of Conflict of Interest. During the reporting period, IT and other departments
we issued the notice on strengthening Compliance Management of Tigermed , and appointed involving personal information For anti-corruption and compliance: compliance.officer@tigermedgrp.com;
Email addresses
compliance and data security officers to strengthen compliance management across the of project personnel. We invited For data security: DPo@tigermedgrp.com
european lawyers to carry out Clearing
Company. As our presence in the global marketplace increases, we employ local legal consultants assessment and certification,
Reporting The tips will go straight to our compliance officer / data protection officer, who will set up a
and develop standard operating procedures (soP) to align operations to local policies and and organized training sessions
working group for investigation, and deal with the reported matters according to investigation
regulations. For example, we come up with Tigermed Physician Payments sunshine Act referring for all employees to enhance Channels results. Since the establishment of the reporting channels, the Company has not received any
the awareness of personal
to relevant regulations in the United states to meet compliance requirements. information protection and reports on compliance violation.
compliance management.
10 11
CoRPoRATe GoVeRnAnCe
Tigermed
Sustainability report
Risk management and control Csr management
We have built a corporate governance structure consisting of the general meeting of shareholders, As of March 31, 2020 We work tirelessly to integrate social responsibility into corporate governance and operation, and
the Board of Directors, the Board of supervisors and the management, and a risk control push for sustainability management and practices. We also continuously deepen the harmonious
framework of the internal audit department, audit committee and business QA with a clear relationship with stakeholders to safeguard health for mankind, fulfill social responsibility, and
division of duties, either of risk assessment or of risk management strategy. We have also set up
risk assessment and control systems to standardize the management of business, finance, legal
19 achieve sustainable development.
number of registered patents
affairs, internal audit and information to improve security and guarantee sound and sustainable Leading organization and working mechanism
development.
IPR protection
377 We have set up a well-coordinated organizational structure to promote sustainability
management. As a decision-maker, the Board of Directors is charged with the top-level design
number of software copyrights
of sustainable development affairs. The social Responsibility Department, as a coordinator
We have put in place an intellectual property right management system. We manage intangible and supervisor, is responsible for promoting and monitoring implementation progress. The
assets carefully, and strictly abide by provisions of our asset management system, scientific subordinate business units under the guidance of the headquarters perform CsR-related tasks as
research management system, and personnel management system. And we actively reach out designated.
to the national Copyright Administration to apply for and renew software copyrights and utility
model patents. Formulate sustainable development strategies and policies
Decision
board of Directors
Clinical trial ethics maker supervise and review achievements in sustainable
development
We strictly follow the Declaration of Helsinki and include it in staff training in the hope of 100% Implement resolutions of the Board of Directors on
encouraging more employees to understand, support and participate in clinical research, and of Coverage of ethics training for sustainable development
social responsibility
accelerating the R&D of new drugs to contribute to public health. clinical trial practitioners
Coordinator Communicate on and coordinate sustainable development
Department issues
Prepare sustainability reports
Manage esG information on a daily basis
subordinate business
executives Fulfill esG management objectives
units
Provide timely feedback
Tigermed's social Responsibility Management Mechanism
Goals and objectives
We continue to consolidate the foundation of social responsibility management. We focus on
CsR management, responsible practices and sustainability branding to enhance the capacity for
sustainable development and build competitiveness.
Csr management Csr practices sustainability branding
Improve the sustainable Fulfill social responsibility Through releasing social
development mechanism and summarize model cases responsibility reports
and put forth policies in line with our sustainable (sustainability reports),
and systems to promote development strategy and we spread our sustainable
normalized CsR key sustainability concerns development philosophy
management of the industry and gradually create a brand
image as a sustainable
enterprise
12 13
CoRPoRATe GoVeRnAnCe
Tigermed
Sustainability report
Sustainable relationship with stakeholders
We conscientiously identify and manage the impacts of our decisions and operations. We
prioritize material topics closely related to our own development, and regard the government,
shareholders, customers, employees, partners, environment, and community as important
players propelling our continued development. We are committed to answering for each and
every stakeholder.
We refer to Iso 26000 Guidance on social Responsibility, GRI
sustainability Reporting standards issued by the Global sustainability
standards Board, and environmental, social and Governance Reporting
Guidelines of the Hong Kong stock exchange, to benchmark ourselves
against outstanding practices in and outside China. Then, we proceed
from the realities of the industry and our own conditions to identify
material topic
material topics for us and our stakeholders. We maintain active communication with all stakeholders. Through
management Communication diversified mechanisms and channels, we listen to the voices and
To fully grasp the expectations and needs of stakeholders, we with stakeholders concerns of all parties for mutual benefit and sustainable social
conducted research and survey (with 454 valid questionnaires development.
collected), and analyzed material topics from two dimensions, namely
"relevance to stakeholders" and "relevance to Tigermed's sustainable
development" for accurate results.
stakeholders Demands Communication channels
Tax payment according to law Inspection visits by leaders and competent departments
Compliance operation Regular work summary and official document
government and
regulators Fair operation exchanges
Creating jobs Daily policy implementation
High
Quality of products and services The general meeting of shareholders
Protecting the rights and interests of subjects Compliant operations Information disclosure through regular reports and
Raising customers' satisfaction
Protecting the rights and interests of employees shareholders economic performance official website
Tax payment according to law
Employee training and development
and investors Information transparency Investors' hotline
Information transparency Risk management
Employee welfare and care
Work-life balance Business online platform irm.cninfo.com.cn of shenzhen stock
Be Important to stakeholders
Occupational health and safety
performance
R&D ethics Fair operation exchange
Cultivating talents
Responsible supply chain
R&D innovation Product and service quality
Customers, Customer visits
Raising environment protection awareness Promoting industrial exchanges
R&D ethics compliance
Resource conservation
including sponsors Daily communication by email and telephone
and hospitals
Waste management
Environment management Reduce R&D costs
Customer satisfaction surve
Industry-university-research integration
Improve R&D efficiency
Participating in industrial investment Fair partnership Cooperation agreement
Coping with climate change Partners
Responsible procurement Industrial activities, such as exhibitions, and seminars
Organizing public welfare activities
Commitment to community health
Protection of basic rights and interests Internal emails
employees Personal growth and career development Internal publications
Work-life balance Channels of soliciting demands
low
low Be Important to Tigermed's sustainable development High Communities and Health knowledge seminars
Promoting community health
the general public Public consultation and complaints
Tigermed's Matrix of Material Topics
14 15
FeATURe: CoUnTeRMARCHInG, In THe FIGHT AGAInsT CoVID-19
Tigermed
Sustainability report
Rendering Immediate "this spring festival is meaningful. i'm heading out!"
Support to
"i'm a mom. i'm racing for life."
Countermarchers on the
——Guo Tingting, project manager, after hearing the news, immediately informed her
family and rushed to the hospital for help.
Front Line
——Li Mei, after learning that the potential drug was about
to go through Phase III clinical trial, picked up the phone and
volunteered to help with the researcher just ten days after
giving birth to her child. "Darling, wait for me back."
A s the spring Festival of the year of 2020 approached,
FEAturE
CoVID-19 spread rapidly from Wuhan to the whole China. The "Count my dad in."
pharmaceutical industry was racing against the clock to find
——Cao Lianjun, project manager, left
potential effective antiviral drugs and rush to put them in "Please, drive me there asaP!"
his months-old child and hurried off to
clinical trials.
Countermarching,
the hospital to help researchers expedite
——Wan Yan, CRA based in Wuhan,
trials.
recommended her father as a
Among them, one drug showed sound antiviral activity
——Gong Yunyan, CRA based in Beijing, volunteer to support transportation
in the Fight Against
against sARs coronavirus and MeRs coronavirus in early cell asked her sister to drive her to commute work during the Wuhan's lockdown.
and animal experiments, and was regarded as a potential between the hospital and printing stores.
therapeutic drug in the early stage of the outbreak. It was of With their efforts, our clinical trials got "my baby will take pride in me."
COVID-19
great significance to find out its clinical effect and to verify its approved.
efficacy and safety.
An Mingru, an expectant mother at 36
At this critical moment, employees of Tigermed were informed
weeks of pregnancy, still kept on working.
that the China-Japan Friendship Hospital had already kicked off
If one compares the fight against COVID-19 to a the study in Jinyintan Hospital of Wuhan. They volunteered to
war without gunfire and smoke. step into the epicenter and threw themselves into the research.
In addition to the clinical studies (for drugs, diagnostic
Then those people who risk their lives to grapple reagents, and vaccines) at the onset of the pandemic, Tigermed
Issued by the Party Committee of Binjiang District of Issued by Zhejiang Association for Corporate social
Hangzhou City in recognition of the outstanding contribution Responsibility in recognition of Tigermed's impressive sense of
with the lethal virus are not born heroes sent from donated money and supplies to the epicenter through
of Tigermed during the fight against the pandemic. social responsibility and patriotism reflected in the donations.
specialized agencies. In the case of shortage of materials, the
the heaven. Company leveraged its own resources in the medical industry
chain to purchase protective supplies for front-line medical
"binjiang's Power in anti-CoviD-19 fight" 2020 outstanding Contribution award of zhejiang
They are instead, ordinary people sacrificing their personnel. award enterprises in anti-CoviD-19 fight
lives for the greater good.
Tigermed chose to countermarch in the looming
Letter of Thanks to the Family Members of Tigermed Staff
shadow of the pandemic.
In the battle against COVID-19, we deeply appreciate the efforts of your families. It's an honor of
Tigermed to have such a group of excellent employees. We believe they will be able to complete
the task smoothly and look forward to their safe return.
Dr. Ye Xiaoping, Chairman of Tigermed
on January 25, 2020, Dr. Ye Xiaoping, Chairman of Tigermed, and Ms. Ms. Cao Xiaochun, General Manager of Tigermed
Cao Xiaochun, General Manager of Tigermed, along with all Tigermed's
medical staff, donated RMB 2.08 million to support the fight against
CoVID-19 in Wuhan.
16 17
FeATURe: CoUnTeRMARCHInG, In THe FIGHT AGAInsT CoVID-19
Tigermed
Sustainability report
Delivering High-quality Safeguarding Employees'
Service as Always Health Wholeheartedly
At 10:00 on January 23, 2020, Wuhan was locked down, and the "saving others is saving oneself."
fast-running city was put on hold.
Considering the pandemic and the unique nature of clinical trials, we
However, our responsibility towards the sponsors and patients As a company specialized in medical
pay high attention to the health and safety of employees.
never ends. and health services, we stay true to the
After informed of the outbreak before the spring Festival, The Wuhan team did a We established the emergency response team, worked online, supported
mission of "serving healthcare partners
functional teams, provided one-on-one services, initiated employee
marvelous job for the recent
Tigermed immediately established an emergency response
assistance program (eAP), popularized protection knowledge, and sent through innovation, advancing human
team for epidemic prevention and control. We launched
our regards via the Labor Union…
health through excellence". There are
projects. Hope they and their
the business continuity plan (BCP), and made detailed
arrangements for research projects with sponsors to minimize
our care for employees permeate the slightest matters. still cascades of difficulties in beating
families are all fine.
the impact of the pandemic.
The pandemic tests the resilience of all enterprises. Despite the year-
COVID-19. Therefore, we are pressing
After learning Wuhan's lockdown, our project team members
in Wuhan took immediate actions. They entered the research
on-year decrease in business volume, we insist on no salary cuts and no ahead with clinical trials of therapeutic
layoffs to reassure our staff, and do our best to maintain social stability.
center after obtaining permission to transfer project data drugs worldwide to secure the final
urgently and keep the test drugs properly. — Tigermed delivered products on time despite the
pandemic, and was highly praised by our American As of the date of this report, there was not a single case of infection or victory of the battle, and contribute to
To minimize the impact of the pandemic on clinical trials and client. suspected infection in Tigermed.
public health.
ensure the health and safety of subjects, CRAs and project
managers, we introduced various solutions, such as online tigermed timeline of fight against CoviD-19
follow-up, online monitoring, and mailing samples and drugs,
to ensure uninterrupted clinical operations and medication
In response to the government's appeal,
supply to the subjects. Issued a warning Transferred clinical we extended the holiday, postponed work
company-wide to materials and drugs resumption and rolled out emergency response
stay vigilant about during Wuhan's plans for business operation. The functional
the epidemic. lockdown. departments introduced home office measures.
January 20 January 23 February 2
January 21 January 25 February 3
Set up an emergency Donated RMB 2.08 Tigermed staff arrived at Jinyintan
response team headed million to the Red Hospital and officially joined the
by the President. Cross Society of China clinical trials.
Zhejiang Branch.
Issued Tigermed's
Project members for COVID-19 Requirements on COVID-19 Tigermed and
potential drug clinical trial Prevention and Control, Hangzhou Simo were
in Wuhan returned back to specifying protection among the first batch of Completed the
Hangzhou and Changsha and measures after business enterprises approved to first subject
went on to a 14-day quarantine. resumption. resume work. administration.
March 28 February 12 February 10 February 6
April 15 March 20 February11 February 7
All project members Successfully Donated PPEs such as Established Tigermed COVID-19
for COVID-19 potential launched Tigermed protective gowns, face Prevention and Control Team
drug clinical trial in Annual Conference
masks and gloves. specifically for clinical trials project
Wuhan returned home. online.
members in Wuhan.
18 19
Tigermed
Sustainability report
DrIvING INNovAtIoN
poWErING
GLobAL mEDICAL oF CLINICAL
INNovAtIoN
rEsEArCH
Our Actions:
Provide clinical trial services and bring new and effective drugs
to patients
bEComING A
Promote innovation and marketization of pharmaceutical
trustED CLINICAL products
rEsEArCH pArtNEr expand clinical research business in Asia Pacific, north America
and europe
Protect the basic rights and interests of subjects
strengthen quality management and integrate quality control
into the whole supply chain
Innovation is in the genes of Tigermed. The Company
takes innovation as the key to harness changes in
science and technology, in domestic and foreign
pharmaceutical policies, and in customer demand. We
upHoLDING QuALItY embrace innovation in technology, management and
As tHE CorE oF tHE service to speed up corporate development, facilitate
global pharmaceutical R&D, and safeguard the health of
busINEss
mankind.
DRIVING INNOVATION OF CLINICAL RESEARCH
Tigermed
Sustainability report
As of Q1 2020
poWErING GLobAL facilitated the marketing of the first indigenous anti-cancer Drug in the us Case
once, it was taken for granted that effective anti-cancer drugs are
mEDICAL 319
number of clinical research
only developed by foreign companies. only after years of marketing
overseas can these drugs finally enter China, depriving many
INNovAtIoN
projects of Class I Chinese
patients of the best timing for treatment. In november 2019, the U.s.
innovative drugs Tigermed
participated in Food and Drug Administration (FDA) approved Zanubrutinib, a novel
anti-cancer drug independently developed by Chinese biomedical
enterprise BeiGene. Zanubrutinib thus became the first China-
Under the policy guidance of the national pharmaceutical regulators, China's pharmaceutical
industry has ushered in an era of boosting innovative drug R&D rather than confining itself to 36 developed anti-cancer drug approved by the FDA. Hangzhou simo
provided sMo services throughout the clinical research process,
generic drug production. It is now more actively engaged in global pharmaceutical innovation. number of Class I Chinese
innovative drugs gained approval while Frontage Laboratories manufactured the experimental drug
The development and application of innovative technologies such as big data and cloud
to market with the support of and conducted heart safety clinical studies for Phase I trial.
computing also empower the digital transformation of the CRo industry. Tigermed
Powering Drug innovation, bringing Driving the "go global" of China's
Patients new hope innovative Drugs
China is now vigorously promoting the R&D of new drugs. It is committed to launching more In 2019 In 2019 In the wave of the globalization of pharmaceutical R&D, China became a member of the
innovative drugs to the market to endow patients with more options. since its inception in 2004, International Conference on Harmonization (ICH) in 2017 and has aligned with global standards
Tigermed has developed a sound pharmaceutical R&D service system that provides integrated for more global cooperation. To accommodate the growing demands for overseas R&D projects,
and comprehensive clinical trial solutions for innovative drug R&D. 124 116 we actively plan our overseas business layout, and extend our businesses step by step to Asia
R&D investment （million RMB） number of updated and Pacific, europe and the United states to boost our international competitiveness and bring
improved soPs for supporting China's innovative drugs to the international arena.
Tigermed focuses on clinical global project cooperation
trial operation services for Tigermed provides other
innovative drugs, generic drugs
and medical devices, as well Clinical-related
important services in the
drug development process,
4.43% Participating in Riding the trend of globalized pharmaceutical R&D, we actively carry out
Clinical trial R&D investment to operating
as complementary services
services and
including data management
revenue international projects multicenter trials worldwide.
directly associated with solutions and statistical analysis, site
clinical trial operations such
laboratory management and patient
as medical writing, translation services recruitment, medical imaging
and registration services and
pharmacovigilance services.
as well as laboratory services.
7 Building strategic We join hands with overseas pharmaceutical enterprises and laboratories
services for Pharmaceutical Innovation
Among the 13 Class I drugs partnership to promote innovation and research.
approved in China, 7 were
developed with the assistance of
Contributed to the approval of the first China-made artificial heart "yongrenxin", Tigermed or its subsidiaries.
Case
creating a medical miracle to regain a new life by new heart
Joining hands with We communicate with overseas pharmaceutical organizations and learn
Patients with heart failure and in need of heart transplantation overseas organizations from their best practices to narrow the gap.
are often plagued by problems such as the lack of donors and the
necessity of long-term anti-rejection and anti-infection treatments.
The artificial heart has brought new hope for such patients. To the first subject successfully enrolled in singapore for international multi-
Case
break the monopoly of developed countries in the artificial heart Center trials
technology and better address the needs of domestic patients,
artificial heart "Yongrenxin" developed by Chongqing Yongrenxin In July 2019, Jiangsu Alpha Biopharma Technology's study of the new generation of oral small-
Medical Devices was approved to be launched in the market in molecule reversible epidermal growth factor receptor (eGFR) tyrosine kinase inhibitor (TKI) -
August 2019. Tigermed provided clinical research and technical AZD3759 successfully enrolled the first subject for a Phase II/III international multi-center trials
services throughout the product's R&D. "Yongrenxin" fills the and finished administration in singapore. For Tigermed, this is the first international multicenter
technical gap in the field of artificial heart in China. The innovative trial project and the first subject enrollment in singapore, which sets a shining example for
product will rekindle the hope of patients for life. following research and development in southeast Asian countries.
22 23
DRIVING INNOVATION OF CLINICAL RESEARCH
Tigermed
Sustainability report
teddy Clinical research laboratory established strategic Partnership with mlm
Case
(european)
To better adapt to the trend of international multi-center clinical trial cooperation and meet
the needs of global customers, Teddy Laboratory has formally established strategic partnership
with MLM, a european based medical lab. Both sides will carry out extensive cooperation in
international multi-center trials and one-stop laboratory services.
Jiaxing Clinflash officially recognized as a member of CDisC to Deliver high-
Case
Quality service
As an active advocate of the globalization of
clinical trials, Jiaxing Clinflash was recognized
as a gold member of CDIsC in May 2019. CDIsC
is a global open non-profit organization (nPo)
of whole disciplines. It aims to integrate best
practices in the industry and establish unified
standards for clinical R&D, to support the
electronic acquisition, exchange, submission,
and archiving of clinical and preclinical data.
Through CDIsC's platform, Jiaxing Clinflash
will continue to improve its system and service
quality, meet CDIsC standards, and enhance
the efficiency and benefits of pharmaceutical
enterprises.
ushering in organizational reforms in the bEComING A
Digital age trustED CLINICAL
The digital reform in the medical industry has been unveiled and accelerated by CoVID-19. We
rEsEArCH pArtNEr
embrace the changes by integrating innovative technologies into our strategy and decision-
making. We formulate prudent digital upgrade plans to keep up with the fast-pace industrial Tigermed's popularity among customers hinges on the hard-working and pragmatic clinical
transformation, and shoulder due responsibility for customers and patients. research team. We tirelessly extend the industrial chain and build regional service capacity to
provide comprehensive and timely solutions, and strive to become a reliable clinical research
partner for sponsors, clinical trial centers / researchers, and subjects.
We appoint Chief Innovation officer (CIo) for the first time. Through reasonable data
Business data use, we gradually build a digital management platform and an office collaboration
collection platform to improve the transparency and efficiency of business operation, and lay a
solid technical foundation for international collaboration.
The sense of mission is deeply embedded in the mind of Tigermed
Digital business We combine traditional business scenarios with digital technologies to facilitate the
employees. We feel proud when the product we processed is marketed
scenarios innovation, development and application of drugs.
and benefiting patients. The recognition of customers is our perpetual
source of motivation.
We set up an innovation center to enhance the awareness of all staff at all levels, and tap
Digital culture ——Ms. Cao Xiaochun, General Manager of Tigermed
into the potential of each employee for innovation.
24 25
DRIVING INNOVATION OF CLINICAL RESEARCH
Tigermed
Sustainability report
Continuously upgrading service Capacity
To improve the efficiency of clinical trials, we build stronger professional service capacity
to improve customer experience and protect the rights and interests of subjects. We strictly 100%
guarantee the security of clinical trials and research data to safeguard the privacy of all parties. Annual retention rate of top ten
customers
Improve the ability of Protect the rights and Safeguard information
on-site service interests of subjects security
We set up a clinical trial center We sign the Informed We formulate information
management organization Consent Form with subjects security policies and specify
(Hangzhou simo) to assist beforehand to protect their the responsibilities and
research institutions and right to be informed. And we requirements of confidentiality,
researchers in clinical trial provide sponsors and research as well as the processing
management. We have also institutions with patient procedures and transfer
developed standard operating health training and academic requirements of personal data.
procedures (soP) for seminars to protect the safety, We organize regular trainings
Hangzhou simo to standardize welfare and rights of subjects. for all employees to enhance
management and improve the By the first quarter of 2020, their awareness of data and
quality and progress of clinical we had recruited over 7,100 information security. During the
trials. As of the first quarter subjects. reporting period, there was no
of 2020, Hangzhou simo had major information leakage or
provided professional services data/agreement loss.
in 956 sites across 106 cities.
In september 2019, Hutchison MediPharma (shanghai) awarded top-performing suppliers for the first time, and Hangzhou simo won excellent
voice from a CrC: Charging forward with the hope for life Case
Team Award.
establishing Complaint handling
Tigermed is home to teams of hardworking frontline staff in clinical trials, whose daily routine is
full of hustle and bustle. These people choose to march forward with the hope of marketing more
mechanism
new drugs for public use.
"When will Patient 02 be here and has he made an
Patient A failed to store
appointment?" "The data for the interim analysis must be
urine samples from this
ready by next Wednesday." "The first PK blood sample of According to the satisfaction As a service-oriented enterprise, customer satisfaction is our goal. We have built a comprehensive
morning as required;
subject 1001 was hemolyzed just now. Do we need to give survey results in 2019 (10 customer feedback mechanism which allows us to understand customer demand, timely solve
Patient B failed to
additional explanation?" points in total) problems, and improve customer satisfaction through visits, telephone calls, survey and other
complete CT examination
means of communication.
as scheduled; Patient
Receive complaint
As a clinical research coordinator (CRC), he/
she often says the following:
And he/she often
must face such
incidents:
C refused to return for
safety follow-up.
9
Average score of PM satisfaction
of sponsors / CRo
Product Manager analyzes the complaint and forwards the message to relevant
As a CRC, one may thus feel "I am a CRC, a bridge connecting doctors fighting for lives departments / Person in charge
discouraged, but always and patients struggling to survive. To let patients access the
holds on to this belief:
latest treatment, I will not give up." 9.7 Product Manager / Responsible departments / Person in charge handles the
Average score of researchers'
satisfaction of CRC complaint (investigation, solutions, feedback, follow-up)
After years of arduous work, the new drugs are finally put on the market. once again, in the battle
between life and death, our clinical research team seizes the final victory.
Post-solution survey
over the years, I have grown from a novice to a veteran with the memories of dozens of patients
engraved on my mind. There were hard times when mounting difficulties blocked our way; and Customer Complaint Handling Mechanism
there were good times when the new drugs we worked on finally hit the market. eventually, the
good trumped the bad. Marketing a new drug, for doctors, subjects, and CRCs alike means hope The Company keeps detailed records of customer complaints and divides them into four
for survival and for life. categories, namely major (key issues), moderate (serious issues), minor (general issues) and
invalid complaints for efficient management. In 2019, we received 17 complaints from customers
——An anonymous CRC and handled all effectively.
26 27
DRIVING INNOVATION OF CLINICAL RESEARCH
Tigermed
Sustainability report
upHoLDING QuALItY As tHE Cultivating a Culture of Quality
High-quality clinical research results cannot be guaranteed without a powerful culture of
CorE oF tHE busINEss In 2019
quality. We focus on cultivating the quality awareness of employees during production and
operation. Through orientation special training and regular trainings, we gradually change the
way employees work and think, improve their awareness and make sure they understand and
Drug quality concerns life and death. only by putting quality first can Tigermed gain a foothold
4 shoulder due responsibility.
in the market, win more trust and sustain long-term cooperation. We continue to optimize the number of meetings on the
quality management system held the first annual Quality management meeting to improve Quality awareness
quality management system, create a quality culture with full participation of staff, integrate Case
of the leadership
quality control into the supply chain, and work with suppliers to ensure quality throughout the
clinical research process.
1 In september 2019, Tigermed held the first annual quality management meeting in shanghai.
The meeting welcomed 72 senior managers, 66 of which were heads of departments of the
number of annual meeting on
quality management headquarters and subsidiaries in China and 6 were from overseas institutions. The meeting,
Continuously optimizing the Quality
focusing on three themes: quality management, annual quality management activities
and annual quality management audit reports, introduced the Company's annual quality
management system
management progress to the senior managers to consolidate the quality awareness of the
In 2019
management and clinical teams from top to bottom, and create a quality-oriented corporate
culture.
We build a quality control system composed of the Quality Management Committee, Quality
Assurance Department and Internal Audit Department, and constantly upgrade the system
13
number of projects passing
by adopting the PDCA (Plan-Do-Check-Action) approach. In 2019, we integrated the soPs of inspection by nMPA
domestic and foreign subsidiaries to build a unified quality management system, and improved
the current processes in line with the Us and european regulations and the international strategy
of Tigermed to better adapt to global development. 15
We formulated regulations and soPs such as Measures of Handling non-Compliance , and Received 15 audits of both
domestic and overseas customers
Corrective Action and Preventative Action to deal with major or serious quality incidents. our with no major issues found, and
Quality Assurance Department will investigate the incidents at once, implement handling the reception and follow-up work
measures, formulate corrective and preventive measures, and optimize the process according to were highly recognized by our
integrating Quality Control into the
customers.
the PDCA principle to control risks and prevent the recurrence of similar problems.
In 2019
supply Chain
To control quality throughout the clinical research process, we incorporate supplier management
1604 into the soPs, and formulate specific management procedures for suppliers engaged in clinical
number of suppliers trials with key performance indicators. In this way, we aim to further integrate quality control into
the supply chain, and work with suppliers to strengthen quality management.
1028 We have formulated the supplier Management system to clarify the responsibilities and approval
Strict supplier
management
Domestic suppliers authority of buying requisition, approval, purchase, acceptance, warehousing, payment, and
inventory. We select suppliers based on principles like fairness and justice, full competition,
integrity and self-discipline, and evaluate candidates from multiple dimensions to reduce
economic, social and environmental risks threatening product quality and business ethics.
576
overseas suppliers
We include supplier audit into the annual audit plan, and examine the quality performance of
suppliers involved in clinical trials on a regular basis. We carry out on-the-spot on-cause audit of
Supplier
8 quality incidents, and understand the whole operation process from personnel qualification and
audit
training to the establishment and improvement of the quality system through communication, to
number of supplier audits help suppliers identify defects and enhance their quality management system.
completed
28 29
Tigermed
Sustainability report
promotING
INDustrY ACCELErAtING tHE
DEvELopmENt DEvELopmENt oF HEALtH
INDustrY LoCALLY
Our Actions:
Fuel the development of regional healthcare industry
establish platforms for industry exchange and cooperation sHArING IDEAs AND
Cultivate talents for the industry rEsourCEs WItH
empower sMes INDustrY pEErs
As a leading clinical CRO in China, Tigermed leverages
its experience, resources and expertise to build a sound
and enabling healthcare ecosystem together with
industry peers, contributing to health for all.
buILDING A stroNG tALENt
pooL For HIGH-QuALItY
INDustrY DEvELopmENt
Promoting industry develoPment
Tigermed
Sustainability report
assisted in Developing national biomedical industry base in Pingshan District,
Case
shenzhen
The biomedical industry is developing rapidly in the Guangdong-Hong Kong-Macau Greater Bay
Area, one of the most open and economically vigorous regions in China. Tigermed and shenzhen
ACCELErAtING tHE Pingshan District People's Government have entered into cooperation to build an integrated
service platform for clinical research. Building on Tigermed's expertise in the clinical research of
DEvELopmENt oF HEALtH
drugs and medical devices as well as the solid foundation for developing the biomedical industry
in Pingshan District, we make full use of local preferential policies and favorable business
environment to empower more biomedical innovation companies in the area, and to make it a
INDustrY LoCALLY highland for biomedical innovation.
Rising health awareness has led to increasing public demands for high-quality healthcare.
Tigermed seizes the opportunity to assist in the reform of local healthcare industry and
capitalizes on the clinical research expertise and best practices it has built up over the years to
expedite drug innovation and R&D, and benefit more patients.
Tigermed has signed a
framework agreement
with shenzhen
Pingshan District
People's Government
to build an integrated
service platform for
clinical research.
Contributed to the biomedical industry in wuxi Case
Biomedicine is one of the strategic emerging industries of Wuxi City. Tigermed is the first partner
of AstraZeneca in founding Wuxi International Life-science Innovation Campus (iCampus).
We hope to share best practices and achievements in international business with innovative
pharmaceutical companies, help Chinese companies go international, and introduce foreign
innovative drugs and medical devices into China. We are committed to building a patient-
centered and innovation-enabling ecosystem across the entire industry chain.
Dr. Ye Xiaoping (right
front), Chairman of
Tigermed, attended
the iCampus signing
Ceremony.
32 33
Promoting industry develoPment
Tigermed
Sustainability report
sHArING IDEAs AND
rEsourCEs WItH
INDustrY pEErs
Based on professional service capacity in new drug clinical research and rich global resources
for collaboration, Tigermed strives to build a high-level exchange and cooperation platform for
industry partners at home and abroad. Through sharing best practices and opinions, players
in the industry could grasp new frontiers of the industry, come up with new ideas, and thereby
generate continuous industry breakthroughs.
sharing experience
At the 2019 China Clinical Trial organizations . Innovation . Practice summit Forum, Mr. Wu Qiang, Vice
President of Tigermed Project Management Department, introduced the development situation of Chinese
clinical trial organizations, and shared insights about opportunities and challenges brought by the new
early-stage clinical R&D is key to the development of innovative drugs. Tigermed held the seminar clinical trial policy. He also shared the experience of cooperating with clinical trial organizations.
on early-stage Clinical R&D of Innovative Drugs to create opportunities for industry peers to share
experience and insights in this regard.
Tigermed organized the First Anhui Institutional Development Conference to strengthen ties offering advice and suggestions
for industry Development
between CRos and sMos, and improve the efficiency and quality of clinical trials.
Tigermed, together with three subsidiaries: Talent MedConsulting, Frontage Laboratories, and
Jiaxing Clinflash, participated in the Third new Drug Clinical Development summit and shared
Tigermed participated in the seminar of ICH e8 (R1) Guideline on General Considerations for
requirements for new drug application and measures for clinical research risk control.
Clinical Trials organized by the national Medical Products Administration, and offered key
takeaways from frontline practices to help push the Guideline to enter the third phase. In
Tigermed and Korea national enterprise for Clinical Trials (KoneCT) signed an MoU to promote
addition, Tigermed was invited to share its experience as a private enterprise in a meeting
exchanges, cooperation and experience sharing between CRos in the two countries.
soliciting opinions for the Regulations on the Promotion of Private enterprises in Zhejiang
Province.
experience sharing for
gCP improvement
tapping the enormous potential
of innovative biologic drugs
Tigermed shared ways to cut R&D expenditure and shorten the R&D cycle of biosimilars at the 2019
Biopharma Developer Innovation Conference & 1st Turning Point Annual Meeting, to expedite the
"go global" of Chinese new drugs.
Tigermed exchanges with industry peers
Tigermed actively participated in major international conferences, such as the DIA 2019 Global
Annual Meeting, the Biotechnology Innovation organization (BIo) International Convention, BIo-
europe, europe's largest biotechnology partnering conference, and the 38th Annual J.P. Morgan
Healthcare Conference, where the Company shared the latest progress and achievements of
Ms. Chang Jianqing, Vice President of Tigermed Policy and Regulations, was invited to the DIA China Drug
China's clinical research with international counterparts and built a two-way bridge for high- Discovery Innovation Conference, where she introduced key points relevant to clinical research in the Drug
quality medical products at home and abroad. Administration Law of the People's Republic of China.
34 35
Promoting industry develoPment
Tigermed
Sustainability report
our actions value contribution
Tigermed works with top hospitals and
Tigermed jointly established the Beijing has developed a unique and innovative
Clinical Research Ability Training Center CRC training model, which will help the
with Beijing Ditan Hospital, Capital Medical domestic healthcare industry build core
University. competitiveness.
giving lectures
Tigermed co-opens courses on Clinical Tigermed jointly develops clinical research-
Trial Management with Zhejiang related courses with universities and
Pharmaceutical College and Hangzhou colleges, which will help arouse students'
Medical College. interest in clinical research, and thereby
cultivate talents for the industry.
Tigermed built a China-south Korea The China-south Korea clinical research
clinical research exchange and cooperation exchange and cooperation platform
platform and sent lecturers abroad to give creates good opportunities for building an
courses to international industry peers. international industry-university-research
team.
forms of cooperation Tigermed offers internships for more than
20 universities and colleges including
Zhejiang Pharmaceutical College, Tigermed expands employment channels for
internships
shenyang Pharmaceutical University, college students and creates opportunities
nanjing Medical University, Beijing for students to know more about clinical
University of Chinese Medicine, Zhejiang research, so as to build a sustainable talent
Chinese Medical University, China pool.
Pharmaceutical University, and Guangxi
Medical University.
buILDING A stroNG tALENt pooL Tigermed supports clinical research
scholarships
Tigermed set up the "Tigermed education by improving school conditions.
For HIGH-QuALItY INDustrY
scholarship" at Hangzhou Medical
College." Tigermed strives to boost its attractiveness
to talents and enhance the popularity of
clinical research in universities.
DEvELopmENt
Tigermed carries out extensive cooperation to train talents for the future
The CRo industry is currently in a stage of rapid development, with a growing demand for high- Tigermed gives play to its resources and technical expertise to provide financial and technical
quality talents. To achieve further progress and high-quality development, advance preparation support for start-up pharmaceutical companies, contributing to the lasting development of the
and talent pooling matter. We invest a lot in finding industry talents and building a clinical innovative healthcare industry.
research talent pool by adding systematic clinical research courses to the current medical
education curriculum and adding clinical research-related content to the standardized training of
resident doctors. funded Pharmaceutical start-ups to enable their rapid growth Case
At present, pharmaceutical innovation in China is in its infancy, and high-quality innovation
projects are often forced into suspension due to lack of financial and technical support. Tigermed
students may not have a clear idea of what kind of job they want to take. the project of
has directly invested in a number of leading biopharmaceutical companies in China, such as
cooperation between schools and enterprises provides us with a valuable opportunity
CAnbridge, Genor Biopharma and shanghai Zerun Biotechnology. Among them, shanghai
to understand the Cro industry. the project has equipped me with not only theoretical Zerun Biotechnology leads the domestic industry in the clinical progress of the 9-valent HPV
knowledge, but also hands-on skills, and prepared me for the industry and the job in a vaccine. And Genor Biopharma plans to launch several new drugs within two years. Besides
short time. direct investment, we have also invested in eight leading domestic healthcare funds, in the
hope of providing both financial and intellectual support to innovative healthcare industries like
———Xu siqing, an intern and then an employee of Tigermed
innovative drugs, innovative medical devices, medical AI, big data, and cellular immunotherapy.
Graduated from Zhejiang Pharmaceutical College in 2019 our investment will empower recipient enterprises and drive the development of China's
healthcare industry.
36 37
Tigermed
Sustainability report
GuIDING our pEopLE
ENsurING EmpLoYEEs'
bAsIC rIGHts AND
IN tHE QuEst For
INtErEsts
suCCEss
Our Actions:
Protect the fundamental rights and interests of employees
Pay attention to employee growth and development
ACtIvAtING tALENt
Care for female employees
AND uNLEAsHING
potENtIAL
Talents are invaluable assets and the cornerstone of
sustainability for Tigermed. We always put people first,
respect the value of employees, and support them in
career development. While helping employees grow and
fulfill themselves, we retain them and grow into a talent-
backed industry leader.
FostErING AN
ENGAGING tIGErmED
CuLturE
GuidinG Our PeOPle in the Quest fOr success
Tigermed
Sustainability report
a People-centered approach for
Common Development
Talents define Tigermed's core competitiveness. While we are growing fast, we adopt
a more scientific and reasonable approach in selecting, employing, training and
retaining talents. our employees have a strong sense of happiness, not only because
they echo with our corporate culture, but also because they find Tigermed to be the
right place for unleashing their talent. While our employees strive for excellence in
Ceo's view work, we give them all-round support and care in mental health counseling, relocation
on talents and returning to work after childbirth, etc. such challenges are fully identified and
properly handled at Tigermed. We are committed to becoming a talent magnet in the
CRo industry and keep investing in a stable and high-quality talent pool.
ENsurING EmpLoYEEs' bAsIC Consolidating the Compensation and
rIGHts AND INtErEsts Performance management system
Tigermed offers diversified salary packages to win the war for talent in the pharmaceutical R&D
We act in strict accordance with relevant laws and regulations, such as the Labor Law of the industry. We combine salary with equity incentives, and evaluate the performance of employees
People's Republic of China and the Company Law of the People's Republic of China, international 100% by introducing multi-dimensional KPIs to perfectly balance employees' efforts and gains. We
have formulated a set of human resource management systems such as the employee Handbook ,
conventions and labor standards, and eliminate child labor and forced labor. We effectively employee labor contract
protect the legitimate rights and interests of employees, and endeavor to maintain equal and signing rate organization Performance Management system , employee Performance Management system and
harmonious labor relations. All our employees are treated equally regardless of gender, age, Remuneration Management system , to ensure the openness and transparency of the performance
educational background, ethnicity and nationality, and enjoy equal and inclusive development evaluation standards and procedures for directors, supervisors and senior executives, as well as the
transparency and law compliance of the appointment of senior executives.
and promotion opportunities. 100%
Key indicators occupational health and safety
social insurance coverage
employees Professional teams excellent educational background employees worldwide Tigermed defines occupational health as mental and physical health.
To ensure that clinical laboratories are health-friendly and safe, we
4959 have formulated safety management systems such as the Laboratory
Technical staff Master's degree Asia-pacific region [China included]
Facilities, environment and sanitation Procedures , and Procedures for
4959 89.31% Financial
staff
1.63%
and above
25.29% 239 Responding Risks and opportunities , to keep testing and environmental
number of employees Asia-pacific region [China excluded] facilities under strict control. We also arrange annual health checkups for
Marketing
employees, and all our employees received health checkups last year.
staff
1064 2.88%
Administrative
Junior
college and
lower
Bachelo's
degree
428
north America The CRo industry is full of challenges, and employees face high pressure
number of employees of staff from work and interpersonal relationships. To help employees better
the parent company
11.71% 63.00%
6.18% 12 address challenges, we have launched the employee Assistance Program
europe
(eAP), the first of its kind in the CRo industry.
Note: The statistics above were current as at the end of December 2019. Please refer to “KEY PERFORMANCE” on P52-53 for more HR statistics.
40 41
GuidinG Our PeOPle in the Quest fOr success
Tigermed
Sustainability report
During the reporting
period
Sparing no efforts in empowering employees
ACtIvAtING tALENt AND Tigermed provides targeted training programs to employees at different levels and
uNLEAsHING potENtIAL 3580 Training
positions. From new hire training to MBA and eMBA degree education for senior
executives, from vocational skill training to management capacity building, we are
number of employees trained
committed to providing employees with uninterrupted and full-course training
resources, to empower them and render them into productive, efficient and creative
Tigermed continues to help employees boost their value. We have formulated the Training
Management Policy, Personal Training and relative soPs, and on the basis of which, established a
37 talents who have excellent problem-solving skills and take pride in their jobs.
Average training hours per
full-coverage, multi-pronged training framework. At Tigermed, one can learn anywhere, anytime employee
as long as he or she wants. We offer a platform for employees to grow fast, and thus nurture and Project Manager Enabling Program
retain the high-quality talent team.
4.67 To help employees better adapt to the new role as Project Manager (hereinafter referred to as PM), grow faster
and improve team productivity, Tigermed has customized a two-year Backbone PM enabling Program. The
During the reporting Investment in employee training program aims to help PMs consolidate basic know-how, improve the ability of managing clinical trial projects,
period （million RMB） strengthen hands-on skills, and thereby lay a solid foundation for career development.
Launching the recruitment management system
Book-reading and sharing employees formulate IDPs
To meet the needs of Tigermed's group-oriented and international development, The Direct Manager provides assistance and
and to build an employer brand of Tigermed, we integrate the recruitment of all
subsidiaries into one platform, and launch a recruitment management system
192 sharing project management
skills lea
rn in
g
ID
P reviews IDP progress on a quarterly basis
number of employees promoted HRBP serves as the supervisor
Selection
up
for full-process human resource management, including job vacancy posting, through the professional talent
Gro
candidate screening, ability assessment, and talent pool construction. The platform channel Project review and summary Coaching PMs in key learning points every
h a ri n g
allows us to continuously improve recruitment efficiency, and find top talents who month, helping them adapt to the new role
Coachi
Project experience sharing
fit in with our vacancies and agree with our corporate values, thus laying a good and build capacity
120
es
Case sharing
ng
foundation for medium and long-term development of Tigermed. Trainees take notes in the monthly coaching
as
C
Training
number of employees promoted HRBP serves as the supervisor
through the managerial talent
channel specialized knowledge Best practices in clinical trial project management General skill training
Expanding the career development ladder The PM training program is mainly in five forms: IDP (Individual Development Plan), coaching, training, case
sharing, and group learning. It aims to unleash constant and conscious enthusiasm of trainees for learning and
We offer a dual career development ladder for technical and managerial talents to growth and enable them to learn by themselves, so as to sustain long-term individual development.
give full play to each employee's ability in the most suitable position and to fully
recognize the value created by employees in different positions. To meet the needs
Employment
Private Board meetings for senior executives
of business development, we added a site management promotion channel during
the reporting period as a novel and exclusive pipeline for CRCs on the frontline of senior executives at Tigermed often need to cope with complex and everchanging issues. only with higher
overall quality and leadership can they address challenges smoothly. During the reporting period, we
clinical research.
organized three private Board meetings for the senior management team and invited coaches to strengthen
their leadership and corporate management skills. At the same time, senior executives were paired up to solve
management problems together. such methods have helped improve the cohesion and capabilities of our
senior management team.
internal Job transfer encourages Proactive Career management of employees Case
During the reporting
period
Tigermed is fully aware that employees may seek job transfer at different stages of life Retaining key talents with incentive policies
due to personal or family reasons, to obtain opportunities for further fulfilling themselves. During the reporting period, Tigermed continued to foster the KPI-oriented corporate
To this end, we have put in place an internal job transfer mechanism. When an employee
535 culture mainly based on company-level and department-level bonuses. We also
Key technical (business) Retention released incentive measures such as equity incentives for talents at key positions
applies for a job transfer, as long as there is a vacancy and the applicant is qualified, he personnel participating in the
equity incentives program and core managerial personnel, and continuously enhanced the competitiveness of
or she can switch the role unimpededly. During the reporting period, 55 employees had our overall compensation package to attract outstanding external talents to join us.
switched positions, including CRCs, CRAs and senior executives who have been with our employee turnover rate is lower than the industry average.
Tigermed for more than 15 years.
42 43
GuidinG Our PeOPle in the Quest fOr success
Tigermed
Sustainability report
FostErING AN supporting work-life balance of employees
ENGAGING tIGErmED Tigermed attaches great importance to the work-life balance of employees and encourages
employees to work hard and live a healthy life. We vigorously enrich employees' cultural life by
CuLturE
providing benefits such as badminton clubs, football clubs, photography clubs, and free gyms to
ease their work pressure. employees are encouraged to participate in public welfare activities.
They donated clothes to Limin Vocational school in Yushu Tibetan Autonomous prefecture
Tigermed cares about how employees feel, listens to their needs, and provides them with all- of northwest China's Qinghai Province via the second "Love transcending distance" activity,
round care and support, making the Company a big loving family. and donated KRW 2.89 million (about RMB 17,315) to an orphanage in south Korea to support
children in need. By doing this, employees themselves have become more responsible and more
grateful.
an unblocked internal Communication
mechanism that allows employees to
share their views
Tigermed endeavors to establish an efficient internal communication mechanism that meets
the new demands brought by business expansion and fresh blood, and ensures the accuracy,
timeliness and transparency of information transmission.
Senior leadership
We inform employees of the Middle management
Company's strategy and business
performance, commend We optimize the reporting and Employee engagement
outstanding employees, and instruction mechanism, and
send holiday greetings via the share professional knowledge employees can give feedback
email of the President office of and best practices across the and suggestions on corporate Tigermed northern China Badminton Competition 2019
Administration, annual meetings, Company through monthly development through the
Caring for female employees
celebration activities, and HRBP meetings, Monthly Talking Points internal IT platform, employee
email. and live streaming. salons, Tigermed innovation talks
and various other channels.
Internal Communication Mechanism of Tigermed Tigermed pays attention to the workplace and life challenges faced by female employees, and
68.29% responds to national policies of guaranteeing benefits and career development opportunities for
women. We make it easier for female employees to become mothers by providing wedding leave,
Women in management
maternity leave, breastfeeding leave, prenatal care check-up leave, pregnancy leave, and birth
control leave, and allow paternity leave for male employees. According to work arrangements,
we create work flexibility for female employees in pregnancy and provide them with child
care subsidies of the highest local standard. Moreover, we have set up maternity rooms in the
2.67% Company to support new moms return to work. As of December 31, 2019, more than 1,000
"Tigermed babies" had been born.
A year-on-year increase of
Reading salon for new employees to be familiar with corporate culture "Tigermed babies"
44 45
Tigermed
Sustainability report
CoNtrIbutING
to A sHArED
FuturE
GrEEN tIGErmED:
strENGtHENING
Our Actions: ENvIroNmENtAL
Popularize knowledge of clinical trials mANAGEmENt
support the "small shield" project for blocking hepatitis B
mother-to-child transmission
Regulate waste disposal strictly
Advocate green office
Healthy ecosystem and social system are the foundation
for the survival and development of mankind. As a
member of the global village, Tigermed links its own
development with the goal of sustainable development
of the world. While supporting drug R&D to protect
people's health, we actively respond to climate change
and other environmental challenges faced by the
world, and take on the responsibility to increase public CArING tIGErmED:
awareness of clinical trials, so as to change the world for ImprovING HEALtH
the better.
AWArENEss At
CommuNItY LEvEL
Contributing to a Shared Future
Tigermed
Sustainability report
GrEEN tIGErmED: saving resources
strENGtHENING In 2019 We strictly control water and electricity use by continuously strengthening the inspection and
maintenance of water equipment and facilities, phasing out outmoded electricity-consuming
appliances, and managing water and electricity consumption statistics. We have enhanced
ENvIroNmENtAL mANAGEmENt 0.0640
electricity consumption per
employees' awareness of resource conservation through communication, putting up slogans
on saving water and electricity and other means to help build a resource-saving society. We use
capita (10000 kWh) municipal water and haven't posed any major risk to the environment.
Tigermed strictly complies with laws and regulations, such as the environmental Protection
Purchased electricity by Tigermed's possessed
Law of the People's Republic of China . We pursue green development in everyday office tasks
and clinical research, and have gradually developed our own eHs (environment, Health and 32.6087 2017
and leased properties (Unit: 10000 kWh)
128.9931 2017
Water consumption (Unit: Ton)
61298
safety) management system by drawing from best practices of advanced industry peers. We Water consumption per
capita （ton）
are also integrating green development requirements into business operations to reduce our
environmental footprint and achieve green development. 2018 125.9178 2018 58268
regulating waste Disposal strictly
2019 103.3363 2019 52663
30 60 90 120 150 50000 53000 56000 59000 62000
The Company's non-hazardous waste mainly includes office wastepaper, cleaning supplies waste, In 2019
food waste, and hazardous waste mainly consists of toxic liquid waste generated during clinical
trials. Reducing waste discharge is one of our environmental goals. To fulfill the goal, we sort
and manage non-hazardous office waste in a rigorous manner, and handle it to environmental
88.453
non-hazardous waste such as
protection authorities for proper treatment on a regular basis. Laboratory environment domestic and office waste (ton)
management procedures have been formulated. And a specific department was established to
be in charge of registering and handling laboratory waste, helping strengthen laboratory waste
treatment and prevent the waste from affecting water and soil. 0.055
emissions per capita （ton）
Poured into designated recycling bins for waste liquid and
low-toxic and non-toxic waste liquid
collected regularly by partner agencies
Laboratory waste disposal
waste acid and alkali Discharged after being neutralized with dilute alkali or acid
Chemical experiments that produce exhaust gases are done We hand over hazardous office
exhaust gas waste, such as empty toner
in labs with fume hoods to treat and vent exhaust gases
cartridges and waste fluorescent Catchy electricity slogan in the office area
tubes, to third-party agencies
Combating Climate Change
everyday solid waste Landfilled after collection
or the real estate management
service for disposal. In 2019
biological waste Inactivated before disposal
As a CRo, Tigermed's day-to-day energy consumption mainly comes from electricity consumption
181.561 of office equipment such as computers and lighting facilities, and oil consumption of vehicles.
We keep a close eye on the impact of our daily operation on climate change, and work hard to
The Company's total direct
and indirect greenhouse gas reduce pollution by launching a remote online collaborative office system, promoting green office
emissions decreased by 181.561 (such as replacing printed business cards with electronic ones), and effectively controlling and
tons Co2e on a year-on-year
managing self-owned vehicles.
basis.
831.444 65.834
Note: Please refer to "KEY Indirect greenhouse gas (scope 2) Direct greenhouse gas (scope 1)
PERFORMANCE" on P52-53 for the emissions （ton Co2e) emissions （ton Co2e）
scope and calculation method of
environmental data, and more 0.515 0.041
emissions statistics. emissions per capita （ton Co2e）
emissions per capita （ton Co2e)
Calculated based on the Company's Calculated based on the Company's
purchased electricity gasoline consumption
48 49
Contributing to a Shared Future
Tigermed
Sustainability report
CArING tIGErmED: ImprovING Q Subject A Doctor
HEALtH AWArENEss At we answer questions
from subjects on the Doctor, are the trials and tests free? What obligations
CommuNItY LEvEL
CrPf official weChat do I need to fulfill?
account:
The development of an enterprise is inseparable from the engagement and support of the Hi, we encourage and respect every subject for the clinical trials of a new drug. since
community, while the development of a community also requires the invention and contribution the uncertainties and safety issues are unknown before a new drug is launched to the
of enterprises. For Tigermed, health is a key issue on our agenda to contribute to community market, to avoid risks, it is necessary for subjects to take regular tests in accordance
development. We strive to open a communication channel between the Company and society, with the protocol. In this way, to comply with necessary obligations is to better
spread our health philosophy to more people through benign interactions, and thereby enhance protect the rights and interests of subjects themselves, and to ensure the safety of
health awareness of the entire society. clinical trials.
Popularizing Knowledge about the the CrPf uses vivid
Clinical trials of Drugs animation to disseminate
knowledge about clinical
trials to the media and the
Clinical trials are still misunderstood by the general public. Most people believe they will be
public:
treated like "guinea pigs" in such trials and won't benefit much. However, clinical trial is a key
link before bringing a new drug to the market, and the participation of subjects is indispensable. scan the QR code to learn about scan the QR code to learn about
clinical trials of new drugs clinical trials of generic drugs
In fact, subjects could access new drugs or new therapies with better efficacy for free in clinical
trials. Thus, Tigermed is actively popularizing knowledge of clinical trials among the public,
helping the general public, especially subjects, know that such trials are scientific and advanced.
By doing this, the Company contributes to building a healthy, virtuous, and trustworthy my genuine opinion (on being a subject) is that patients spend less or even no money
pharmaceutical R&D ecosystem. to get good treatment, while also providing true data for the r&D of the new drug and
paving the way for future drug users. it is beneficial to the subjects themselves, to drug
r&D institutions, and to future subjects.
In september 2017, Tigermed and large hospitals, pharmaceutical
companies and other organizations from across China jointly
established the Clinical Research Promotion Fund (CRPF), and opened ———A comment on the CRPF official WeChat account
an official WeChat account to popularize clinical research knowledge,
publish latest news on clinical research, and educate subjects.
blocking mother-to-Child transmission of
hepatitis b with the "small shield"
In 2015, the "Zero Mother-to-Child Transmission of Hepatitis B" project (the "small shield"),
in november 2019
initiated by the Chinese Foundation for Hepatitis Prevention and Control and fully supported
The "small shield" APP by Tigermed, was officially launched. With the establishment of the management network that
obtained the medical device includes pregnancy demonstration bases, project hospitals and community-level hospitals, and
license of Auxiliary Management
software for Blocking Mother- with the help of the "small shield" APP, a mobile medical tool developed by the Company's
to-Child Transmission of investee Hangzhou slanHealth Co., Ltd., the project aims to carry out follow-up management of
Hepatitis B issued by the pregnant women with hepatitis B and their babies in accordance with standard procedures to
Zhejiang Medical Products
Administration. It was the first minimize or even completely block mother-to-child transmission of the disease. As of the end of
officially approved mobile APP the reporting period, the "small shield" project had covered nearly 200 hospitals in 31 provinces,
software device license in the municipalities, and autonomous regions, with more than 1,600 registered doctors serving 30,000
field of liver disease prevention
and treatment since the expectant mothers carrying hepatitis B virus. The success rate of blocking mother-to-child
implementation of the new list. transmission was above 99.5%.
50 51
KeY PeRFoRMAnCe
Tigermed
Sustainability report
Social performance
indicator Unit 2019 2018 2017
Total count of active employees / 4959 3898 3214
Female employees / 4217 3233 2667
employees aged 30 and below / 3623 2874 2320
employees aged 31 to 50 / 1296 994 860
employees aged 51 and above / 40 30 34
Women in management % 68.29 65.62 66.84
Average paid vacation days / 13.85 12.34 9.3
Hse investment RMB 10000 740 620 460
Health checkup coverage % 100 100 100
staff turnover rate % 18.7% 20.7% 23.0%
Work-related fatalities / 0 0 0
number of suppliers / 1604 1896 1507
Cumulative donations RMB 10000 870.60 767.60 652.60
Environmental performance
indicator Unit 2019 2018 2017
KEY non-hazardous waste such as domestic waste and office waste
Purchased electricity by Tigermed's possessed and leased
Ton 88.453 73.950 59.520
10000 kWh 103.3363 125.9178 128.9931
pErFormANCE properties
Water consumption Ton 52663 58268 61298
Mileage of the Company's light vehicles (<=2.5 tons) Kilometer 112567 105548 95477
Economic performance Mileage of the Company's light vehicles (2.5-3.5 tons) Kilometer 132000 130000 135000
indicator Unit 2019 2018 2017 Gasoline consumption Liter 24312 24264 23332
Total assets RMB 100 million 75.33 42.80 35.83 emission of nitrogen oxides Kilogram 252.03 243.51 240.37
operating revenue RMB 100 million 28.03 23.01 16.87 emission of particulates Kilogram 23.74 22.93 22.61
net profit of shareholders of listed companies RMB 100 million 8.42 4.72 3.01 emission of sulfur oxides Kilogram 0.36 0.37 0.34
Taxes payable RMB 100 million 1.12 0.79 0.43 Direct greenhouse gas (scope 1) emissions Ton 65.834 65.704 63.180
Basic earnings per share RMB per share 1.13 0.94 0.61 Indirect greenhouse gas (scope 2) emissions Ton 831.444 1013.135 1037.878
number of R&D personnel / 468 426 378
note 1: The environmental data comes from Tigermed's Hangzhou office, Jiaxing office and shanghai office. The Company will gradually expand
Proportion of R&D personnel % 9.44 10.93 11.76 statistics management to cover the entire group.
R&D investment RMB 100 million 1.24 0.88 0.50 note 2: The emission of nitrogen oxides and particulate matter are calculated based on the mileage of light vehicles held by the company; the emission
of sulfur oxides and direct greenhouse gases (scope 1) are calculated based on gasoline consumption; and the emission of indirect greenhouse gases
R&D investment to operating revenue % 4.43 3.83 2.94 (scope 2) are calculated based on purchased electricity. The calculation method is in line with the environmental KPI reporting principles in the
environmental, social and Governance Reporting Guide (esG Guide) formulated by Hong Kong stock exchange. The emission coefficient of indirect
Drug clinical research project / 287 283 218 greenhouse gases (scope 2) is 0.8046, which is derived from the China Regional Power Grid Baseline emission Factors for emission Reduction Projects
in 2017 issued by the Ministry of ecology and environment.
52 53
oUTLooK
Tigermed
Sustainability report
talent strategy
In terms of human resource management, we will
stick to the people-centered approach for common
development, and create a sound development platform
Quality and qualification for employees. We retain employees with corporate
culture and career growth opportunities, and grow along
In an ever changing world, change is the
Riding on the global trend of pharmaceutical
with them.
R&D, we will consolidate soPs of subsidiaries,
only constant. successful organizations
continuously optimize quality management
procedures, and foster a quality culture with
bear the mark of the times.
full participation of employees, in an effort to
build Tigermed into a CRo aligned with global
quality management standards.
excellent operation
——by John P. Kotter, author of Leading Change We have established a global operation system. With
a competent and stable team and reliable quality
assurance, we will be able to deliver 100% projects
on time with guaranteed quality, and sustain our
competitive profitability.
market strategy
We pay attention to new business drivers such
as real-world evidence (RWe), with a focus on Customer first
developing non-regulated businesses. We will We are always customer-focused. We will timely learn
outLooK go global together with our customers, and
build an international operation team with the
and analyze the needs and expectations of customers
and the market, and continue to optimize customer
support of overseas projects of our strategic relationship management, improve the communication
customers, so as to expand our market to mechanism and complaint management, and strive to
In the global wave of pharmaceutical innovation, the emergence of new technologies like big data
the Asia-Pacific, north America and Western become a trustworthy clinical research partner.
and AI and breakthrough therapies will change the original CRo model. As China has become
europe.
the second largest pharmaceutical market in the world, and Healthy China 2030 has become a
national strategy, the government is now vigorously promoting pharmaceutical innovation by
tigermed will actively embrace the
mounting policy, capital, and industry support.
era of pharmaceutical r&D and innovation, stand firm on being quality-
oriented and innovate in services to cope with changes in the industry and
across the world.
In 2020, Tigermed will stay true to the mission of "service innovation, health for all" and
adhere to the strategy of "excellence in every Trial for every Patient" to serve the cause of innovation-driven development responsibility management
innovative medicine. we will orient our efforts toward customer demand and We closely follow frontier technologies in the industry We will further implement the sustainable development
globalization, expedite the set-up of a global clinical service network, and develop our own leading technologies based on philosophy by formulating and improving policies
and continuously improve the ability of operating and managing global strengths in different business lines. We will follow up and regulations and strengthening the roles of key
with innovative business models such as RWe and risk- departments, especially the Board of Directors, in the
projects, thus providing integrated solutions and one-stop services for
based monitoring (RBM), and improve customer service sustainability management of Tigermed.
global pharmaceutical r&D, and contribute to the health of humankind. procedures through innovation.
54 55
Tigermed HonG KonG sToCK eXCHAnGe esG (enVIRonMenTAL,
Sustainability report soCIAL AnD GoVeRnAnCe) RePoRTInG GUIDe InDeX
HoNG KoNG stoCK EXCHANGE EsG (ENvIroNmENtAL, Information on:
We comply with China's
laws and regulations,
including Work safety Law
soCIAL AND GovErNANCE) rEportING GuIDE INDEX
(a) the policies; and
General of the People's Republic of
(b) compliance and material non-compliance with relevant standards, rules and P41
Disclosure China, and Prevention and
regulations on providing a safe working environment and protecting employees
b2 health and Control of occupational
from occupational hazards
safety Diseases Law of the
This report has complied with the "non-compliance and interpretation" provisions set out in the People's Republic of China
environment, social and Governance Reporting Guidelines. B2.1 number and rate of work-related fatalities P53
B2.2 Lost days due to work injury. /
Description of occupational health and safety measures adopted, how they are
B2.3 P41
implemented and monitored
environmental
aspect General Policies on improving employees' knowledge and skills for discharging duties at
indicator Page note Disclosure work. Description of training activities
P42-43
b3 Development
Information on: The percentage of employees trained by employee category (e.g. senior
and training B3.1 P43
(a) the policies; and management, middle management)
General
(b) compliance and material non-compliance with relevant standards, rules and P48-49 B3.2 The average training hours completed per employee by employee category P43
Disclosure
regulations on air and greenhouse gas emissions, discharges into water and land,
and generation of hazardous and non-hazardous waste Information on:
General (a) the policies; and
P40
A1.1 The types of emissions and respective emissions data P53 Disclosure (b) compliance and material non-compliance with relevant standards, rules and
b4 labor regulations on preventing child and forced labor
Greenhouse gas emissions in total (in tons) and, where appropriate, intensity (e.g.
A1.2 P49 standards
per unit of production volume, per facility) Description of measures to review employment practices to avoid child and forced
B4.1 P40
a1 emissions labor
We entrust a third party to
Total hazardous waste produced (in tons) and, where appropriate, intensity (e.g. per dispose of hazardous office B4.2 Description of steps taken to eliminate such practices when discovered / no violation
A1.3 P48
unit of production volume, per facility) waste and do not acquire
General
relevant data Policies on managing environmental and social risks of the supply chain. P11, P29
Disclosure
Total non-hazardous waste produced (in tons) and, where appropriate, intensity (e.g.
A1.4 P48 B5.1 number of suppliers by geographical region P29
per unit of production volume, per facility)
Description of practices relating to engaging suppliers, number of suppliers where
A1.5 Description of measures to mitigate emissions and results achieved P48 b5 supply Chain B5.2 P29
the practices are being implemented, how they are implemented and monitored.
management
Description of how hazardous and non-hazardous wastes are handled, reduction
A1.6 P48 Description of practices used to identify environmental and social risks along the
initiatives and results achieved B5.3 P29
supply chain, and how they are implemented and monitored.
Policies on the efficient use of resources, including energy, water and other raw
Description of practices used to promote environmentally preferable products and
General materials. B5.4 P29
P49 services when selecting suppliers, and how they are implemented and monitored.
Disclosure Resources may be used in production, in storage, transportation, in buildings,
electronic equipment, etc. We comply with China's
Information on: laws and regulations,
Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total
A2.1 P49 (a) the policies; and including Drug
(kWh in '000s) and intensity (e.g. per unit of production volume, per facility) General
(b) compliance and material non-compliance with relevant standards, rules and P26-29 Administration Law of the
Disclosurea
a2 use of Water consumption in total and intensity (e.g. per unit of production volume, per regulations on health and safety, advertising, labelling and privacy matters relating People's Republic of China,
A2.2 P49
resources facility) to products and services provided and methods of redress and Provisions for Drug
Registration.
A2.3 Description of energy use efficiency initiatives and results achieved P49
Percentage of total products sold or shipped subject to recalls for safety and health
Description of whether there is any issue in sourcing water that is fit for purpose, b6 Product B6.1 / no such incident
A2.4 P49 reasons.
water efficiency initiatives and results achieved responsibility
number of products and service related complaints received and how they are dealt
our clinical research of B6.2 P27
Total packaging material used for finished products (in tons) and, if applicable, with not with
A2.5 drugs do not involve
reference to per unit produced applicable
packages Description of practices relating to observing and protecting intellectual property
B6.3 P12
rights
a3 the General Policies on minimizing the operation's significant impact on the environment and
P48-49
environment Disclosure natural resources B6.4 Description of quality assurance process and recall procedures. P27-28
and natural Description of the significant impacts of activities on the environment and natural Description of consumer data protection and privacy policies, how they are
resources A3.1 P49 B6.5 P26
resources and the actions taken to manage them. implemented and monitored
General Information on:
Policies on identification and mitigation of significant climate-related issues which
Disclosure / General (a) the policies; and
aspect 4: have impacted, and those which may impact, the issuer. P10-11
Disclosure (b) compliance and material non-compliance with relevant standards, rules and
Climate Change regulations on bribery, extortion, fraud and money laundering
Description of the significant climate-related issues which have impacted, and those
A4.1 P49 b7 anti-
which may impact, the issuer, and the actions taken to manage them. number of concluded legal cases regarding corrupt practices brought against the
corruption B7.1 / no such litigation
issuer or its employees during the reporting period and the outcomes of the cases.
social
aspect Description of preventive measures and whistle-blowing procedures, how they are
indicator Page note B7.2 P11
implemented and monitored
Information on:
B7.3 Description of anti-corruption training provided to directors and staff. P10-11
(a) the policies; and
General (b) compliance and material non-compliance with relevant standards, rules and Policies on community engagement to understand the communities' needs where
P40-41 General
Disclosure regulations on compensation and dismissal, recruitment and promotion, working it operates and to ensure its activities take into consideration the communities' P50-51
Disclosure
b1 employment hours, rest periods, equal opportunity, diversity, anti-discrimination, and other interests
b8 Community
benefits and welfare
investment Focus areas of contribution (e.g. education, environmental concerns, labor needs,
B8.1 P50-51
B1.1 Total workforce by employment type, age group and geographical region P40 health, culture, sport)
B1.2 employee turnover rate by age group and geographical region P53 B8.2 Resources contributed (e.g. money or time) to the focus area P53
56 57
GRI (GLoBAL RePoRTInG InITIATIVe) InDeX
Tigermed
Sustainability report
Disclosure items Page note
gri 200 economic GRI 103 Management Approach P8-12,P22-29
GrI (GLobAL rEportING INItIAtIvE) gri 201 economic
Performance
201-1 Direct economic value generated and distributed
201-3 Defined benefit plan obligations and other retirement plans
P52
P41,P43
INDEX gri 203 indirect economic 203-2 significant indirect economic impacts
GRI 103 Management Approach
P51
P10-11
205-2 Communication and training about anti-corruption policies and
gri 205 anti-corruption P10-11
procedures
205-3 Confirmed incidents of corruption and actions taken no corruption
This report has been prepared in accordance with the GRI standards: Core option. gri 206 anti-competitive 206-1 Legal actions for anti-competitive behavior, anti-trust, and monopoly
no such litigation
behavior practices
Disclosure items Page note gri 300 environment GRI 103 Management Approach P48-49
102-1 name of the organization P04 gri 302 energy 302-1 energy consumption within the organization P49
102-2 Activities, brands, products, and services P04-06 303-1 Water withdrawal by source P49
gri 303 water
102-3 Location of headquarters P06 303-2 Water sources significantly affected by withdrawal of water P49 no such influence
102-4 Location of operations P06 305-1 Direct (scope 1) GHG emissions P49
102-5 ownership and legal form P04 305-2 energy indirect (scope 2) GHG emissions P49
102-6 Markets served P06 gri 305 emissions 305-5 Reduction of GHG emissions P49
organizational profile
102-7 scale of the organization P06,P40 305-7 nitrogen oxides (noX), sulfur oxides (soX), and other significant air
P53
emissions
102-8 Information on employees and other workers P40
306-2 Waste by type and disposal method P48
102-9 supply chain P29 gri 306 effluents and waste
306-3 significant spills no significant spills
102-10 significant changes to the organization and its supply chain P08
gri 307 environmental
102-11 Precautionary Principle or approach P12 307-1 non-compliance with environmental laws and regulations no violation
Compliance
102-13 Membership of associations P24 gri 400 society GRI 103 Management Approach P38-44,P50-51
102-14 statement from senior decision-maker P02-03 401-1 new employee hires and employee turnover P53
strategy
102-15 Key impacts, risks, and opportunities P02-03,P12 gri 401 employment 401-2 Benefits provided to full-time employees that are not provided to
P40-43
102-16 Values, principles, standards, and norms of behavior P06 temporary or part-time employees
ethics and integrity
102-17 Mechanisms for advice and concerns about ethics P12 404-1 Average hours of training per year per employee P43
gri 404 training and
102-18 Governance structure P08 education 404-2 Programs for upgrading employee skills and transition assistance
P42-43
programs
102-29 Identifying and managing economic, environmental, and social impacts P14
GRI 103 Management Approach P40
governance 102-30 effectiveness of risk management processes P12 gri 405 Diversity and equal
405-1 Diversity of governance bodies and employees P40
102-31 Review of economic, environmental, and social topics P14 opportunity
405-2 Ratio of basic salary and remuneration of women to men P41
102-32 Highest governance body's role in sustainability reporting P13
gri 406 non-discrimination 406-1 Incidents of discrimination and corrective actions taken no discrimination
102-40 List of stakeholder groups P15
gri 408 Child labor 408-1 operations and suppliers at significant risk for incidents of child labor no such incident
102-42 Identifying and selecting stakeholders P15
gri 409 forced or 409-1 operations and suppliers at significant risk for incidents of forced or
102-43 Approach to stakeholder engagement P15 no such incident
Compulsory labor compulsory labor
102-44 Key topics and concerns raised P15 gri 411 rights of indigenous
411-1 Incidents of violations involving rights of indigenous peoples P10 no such incident
Peoples
102-46 Defining report content and topic Boundaries P15,P60
GRI 103 Management Approach P45,P5-51
102-47 List of material topics P15
gri 413 local Communities 413-2 operations with significant actual and potential negative impacts on local no such location of
no restatements of
102-48 Restatements of information communities operations
information
stakeholder engagement gri 414 supplier social
no significant 414-1 new suppliers that were screened using social criteria P11
102-49 Changes in reporting assessment
changes
417-1 Requirements for product and service information and labeling P26
102-50 Reporting period P60
gri 417 marketing and 417-2 Incidents of non-compliance concerning product and service information
102-51 Date of most recent report P60 no such incident
labeling and labeling
102-52 Reporting cycle P60
417-3 Incidents of non-compliance concerning marketing communications no such incident
102-53 Contact point for questions regarding the report P60
GRI 103 Management Approach P10-12
102-54 Claims of reporting in accordance with the GRI standards P58 gri 419 socioeconomic
Compliance 419-1 non-compliance with laws and regulations in the social and economic
no violation
102-55 GRI content index P58 area
58 59
Tigermed
Sustainability report
About
tHIs rEport
reporting Period
The time frame for the report is January 1 to December 31, 2019, though some contents may extend
beyond the stated reporting period.
release Cycle
The report is released annually. And the first social responsibility report was released on August 22,
2019.
reporting boundary
This report covers Tigermed's headquarters and subsidiaries. For the convenience of readers,
"Hangzhou Tigermed Consulting Co., Ltd." is also referred to as "Tigermed", "the Company" and
"we" in the report. "Hangzhou simo Co., Ltd." is referred to as "Hangzhou simo". "Macrostat (China)
Clinical Research Co., Ltd." is referred to as "Macrostat". "Jiaxing Tigermed Data Management Co.,
Ltd." is referred to as "Jiaxing Tigermed". "Jiaxing Clinflash Computer Technology Co., Ltd." is
referred to as "Jiaxing Clinflash". "Hangzhou Talent MedConsulting Co., Ltd." is referred to as "Talent
MedConsulting". "Frontage Laboratories, Inc." is referred to as "Frontage Laboratories". "Fantastic
Bioimaging Co., Ltd." is referred to as "Fantastic Bioimaging", and "Teddy Clinical Research Laboratory
(shanghai) Limited" is referred to as "shanghai Teddy".
reporting Commitment
Tigermed assures that the report contains no false records, misleading information or material
omission, and is responsible for the authenticity, accuracy, and integrity of its content.
Data sources
Data in the report is mainly from the statistical reports and official documents of Tigermed from
January 1 to December 31, 2019.
Compilation Conformance
This report is compiled in accordance with the Iso 26000: Guidance on social Responsibility , the GRI
sustainability Reporting standards (GRI standards) issued by Global sustainability standard Board
(GssB) and the environmental, social and Governance Reporting Guide (esG Guide) formulated by
Hong Kong stock exchange.
Contact us
Corporate social Responsibility Department, Tigermed
email：CsR@tigermedgrp.com
For more information about Tigermed's CsR practices, please go to https://tigermedgrp.com/
note: Tigermed's headquarters (Hangzhou) relocation is estimated to be completed by the end of scan the QR code to give
August 2020. Please refer to our official website for the new address. feedback on the report.
60